INTRODUCTION
============

The enteric nervous system (ENS) is derived from the neural crest, a multipotent migratory stem cell population that develops into a variety of cell types, ranging from craniofacial cartilage and pigment cells to neurons and glia of sensory, sympathetic, and enteric ganglia (for review, see [@B76]). The ENS comprises an autonomous network of thousands of interconnected ganglia, containing a diverse array of neurons and glia, embedded within the walls of the digestive tract. Enteric ganglia regulate muscle contraction, gut secretion, and water balance within the gastrointestinal tract ([@B35]). Throughout life, the ENS functions to regulate peristalsis during digestion, a key aspect of gastrointestinal function. Defects in neural crest migration lead to a spectrum of developmental disorders ([@B66]), including Hirschsprung's disease, characterized by a lack of ganglia formation in the hindgut. This in turn leads to megacolon, in which decreased innervation leads to accumulation of digested food and an enlarged and nonfunctional colon requiring surgical repair ([@B7]).

During development, the ENS mostly derives from the "vagal" subpopulation of the neural crest, which originates adjacent to somite pairs 1--7 ([@B50]; [@B30]; [@B12]; [@B48]). To colonize the gut, vagal neural crest cells emigrate from the hindbrain, enter the foregut mesenchyme, and migrate caudally such that they eventually populate the entire gut, a migration process that takes days and is the longest of any embryonic cell migration ([@B50]; [@B11]; [@B95]). In chicken embryos, the colonization process is largely complete by day 8 of development ([@B50]), in mouse embryos by embryonic day 15 ([@B26]), and in humans by 7 wk of gestation ([@B33]). In zebrafish embryos, the process of migration is complete by the end of 3 d postfertilization (dpf) ([@B68]). Because of their rapid development, transparency, and simple gut development ([@B79]), zebrafish embryos offer an attractive model for studying the cellular and molecular mechanisms underlying ENS development.

In the developing zebrafish embryo, vagal neural crest cells first enter the foregut at 32 h postfertilization (hpf) as two migratory streams from the left and right postotic vagal regions ([@B44]; [@B27]; [@B78]; [@B68]). Once they reach their final destinations, enteric neural crest cells differentiate into neuronal subtypes or glia, subsequently forming interconnected ganglia within the myenteric and submucosal plexuses that run within the mucosa and smooth muscle layers in zebrafish ([@B69]; [@B79]).

Studies aimed at investigating the molecular underpinnings of Hirschsprung's disease have demonstrated a role for several extrinsic signaling pathways and intrinsic effectors in ENS development (for review, see [@B37]). Among these, the receptor tyrosine kinase (Ret), glial cell line--derived neurotrophic factor (GDNF), Sonic Hedgehog (Shh), and the endothelin signaling pathways play important roles in the migration, proliferation, and survival of enteric precursors ([@B84]; [@B63]; [@B80]; [@B49]). Despite many studies, however, little is known about the early stages of vagal and enteric neural crest development. Important remaining questions include the following: What confers their "enteric" identity? Why do vagal neural crest enter the gut at a particular location? How do they know where to stop migrating along the gut?

Meis cofactors are three--amino acid loop extension (TALE)--family homeodomain proteins that control accessibility at Hox-regulated promoters. They are expressed widely in various tissues and perform a spectrum of functions during embryonic development (for review, see [@B16]). The three Meis family members (Meis1--3) control accessibility at Hox-regulated promoters ([@B20]) by forming dimeric or trimeric DNA-binding complexes with Pbx and/or Hox proteins ([@B90]; [@B92]) and thus regulate transcriptional output in a cell-specific manner. Meis and Pbx proteins associate with each other via conserved N-terminal domains, thereby controlling their nuclear localization and ability to participate in DNA-dependent Hox complex activities ([@B8]; [@B57]). Several studies have highlighted the role of Meis proteins in the regulation of progenitor cell maintenance, proliferation, and differentiation during organogenesis. For example, Meis1 serves an essential role in progenitor/stem cell development in various developmental and postembryonic contexts, such as neural stem cell development ([@B6]), hematopoiesis ([@B5]), and thymic epithelial cell progenitor maintenance ([@B39]). Meis2 regulates limb outgrowth ([@B14]), olfactory neurogenesis ([@B2]), human cardiac development ([@B70]), and the differentiation of craniofacial cartilage in zebrafish embryos ([@B59]).

In contrast to Meis1 and 2, about which much is known, little is known about the function of Meis3 other than that it influences posterior hindbrain patterning in zebrafish ([@B92]; [@B89]) and neural induction and neuronal differentiation in the frog hindbrain ([@B24]; [@B1]; [@B28]). Of interest, Meis3 is expressed in the zebrafish foregut environment at 36 hpf, within the lateral plate mesoderm ([@B56]), and has been implicated in early foregut patterning at 24 hpf ([@B25]). Given the integral roles of Meis proteins in diverse patterning and growth events and the role of Meis3 in the foregut, we asked whether Meis3 might influence enteric neural crest migration and/or ENS development in zebrafish embryos. The results reveal novel in vivo roles for Meis3 during ENS development.

RESULTS
=======

*meis3* is expressed in the developing foregut environment during vagal and enteric neural crest cell migratory phases
----------------------------------------------------------------------------------------------------------------------

At 33 hpf, *meis3* is expressed in the hindbrain, as well as in the posterior branchial arches and the developing fin buds (arrowhead and arrow, respectively, in [Figure 1A](#F1){ref-type="fig"}). *meis3* is also expressed medially on the ventral side of the embryo, near the foregut (arrow in [Figure 1B](#F1){ref-type="fig"}). This is consistent with previously observed *meis3* expression in the posterior lateral plate mesoderm, which lies adjacent to and overlaps the foregut endoderm at 36 hpf ([@B56]). In serial transverse sections at 33 hpf, *meis3* is expressed in the mesoderm that dorsally surrounds and flanks the developing gut (arrows in [Figure 1, C and C′](#F1){ref-type="fig"}). At this stage, the gut endoderm is a simple epithelium before lumen formation ([@B31]; [@B91]; [@B65]). Postotic vagal neural crest cells migrate toward the developing ventral midline and along the anterior foregut between 32 and 36 hpf ([@B80]; [@B68]).

![*meis3* is expressed with the vagal and enteric neural crest migratory environments during early phases of ENS development. (A) *meis3* transcript within the postotic branchial arches (arrowhead) and the fin buds (arrow) at 33 hpf. (B) After yolk sac removal, a ventral view shows *meis3* expression field within the posterior branchial arches and the fin buds and within the foregut (arrow). (C, D) Serial adjacent sections reveal *meis3* localization within the hindbrain neural tube and mesenchymal layer of the developing gut (arrows), just above the developing gut endoderm (dashed circle above yolk). (D--D′′) Double fluorescence in situ hybridization reveals that *meis3* (red) is expressed in the gut and its surrounding environment at 36 hpf and that *crestin*^+^ neural crest cells (green) migrate into and localize within the *meis3*^+^ region. fb, fin bud; nt, neural tube; ot, otic. Scale bars, 50 μm (C, C′), 40 μm (D--D′′).](3728fig1){#F1}

In transverse section, double fluorescence in situ hybridization for *meis3* and the panneural crest marker *crestin* at 36 hpf revealed the presence of *crestin*-positive cells migrating from the lateral mesoderm toward the developing gut ([Figure 1, D and D′](#F1){ref-type="fig"}′, arrows). *meis3* was detected in the mesoderm surrounding the gut and in a subset of the *crestin*+ neural crest cells migrating toward the gut ([Figure 1, D′ and D′](#F1){ref-type="fig"}′, arrows). Taken together, these data indicate that *meis3* is present in the developing vagal and foregut regions during neural crest cell entry.

Loss of Meis3 leads to delayed migration of vagal neural crest cells into the developing foregut
------------------------------------------------------------------------------------------------

The spatial expression pattern of *meis3* near the foregut suggested that it might play a functional role during enteric neural crest and/or foregut development. To test this, we performed loss-of- function experiments by using two strategies to knock down Meis3 at the one-cell stage in Tg(-4.9*sox10:*GFP) transgenic embryos, hereafter referred to as *sox10*:GFP: 1) by use of a translation-blocking morpholino ([@B25]) or 2) by injection of mRNA encoding a dominant-negative Pbx4 construct (*pbcab*) that prevents nuclear entry of Meis proteins ([@B21]). At 25 hpf, Meis3 morphants and *pbcab*-injected embryos exhibited reduced brain and eye size compared with control-injected embryos (Supplemental Figure S1, A--C), in agreement with previous studies demonstrating a role for Meis proteins in eye and brain development ([@B9]; [@B38]). To examine the localization of *sox10:*green fluorescent protein (GFP)^+^ neural crest cells after Meis3 knockdown, we performed whole-mount immunohistochemistry with a GFP antibody. In control embryos at 28 and 36 hpf, *sox10:*GFP^+^ neural crest cells migrated anteriorly around the eye, into the hyoid arch, and into the branchial arches (Supplemental Figure S1D and [Figure 2A](#F2){ref-type="fig"}; *n* = 20/20). In Meis3 morphants (Supplemental Figure S1F and [Figure 2B](#F2){ref-type="fig"}; *n* = 18/20) and *pbcab*-injected embryos (Supplemental Figure S1E; *n* = 17/20), *sox10:*GFP^+^ neural crest cells also migrated around the eye, into the hyoid arch, and into the branchial arches, indicating that neural crest specification was unaffected. Demonstrating the specificity of the morpholino, Meis3 protein levels significantly decreased after Meis3 morpholino treatment and were rescued after coinjection of *meis3* mRNA, which cannot be bound by Meis3 MO, with Meis3 MO (Supplemental Figure S1G).

![Meis3 is required for the timely migration of vagal neural crest to the developing foregut during early phases of ENS development. (A) Control-injected and (B) Meis3 MO--injected embryos at 36 hpf display *sox10*:GFP^+^ neural crest cells around the eye, the hyoid, the otic, and the branchial arches. (C--C′′) Transverse sections depict *sox10*:GFP^+^ cells located laterally within the postotic vagal regions of control embryos and (D--D′′) within Meis3 MO--injected embryos. (E--E′′) Control *sox10*:GFP^+^ vagal neural crest cells are detected within the foregut environment at 36 hpf (E′, E′′; arrows). (F--F′′) virtually no *sox10*:GFP^+^ cells are observed within Meis3 MO--injected embryos around the foregut. F-actin in red (C--F), *sox10*:GFP in green (C′, D, E′, F′) and merge, with 4′,6-diamidino-2-phenylindole (DAPI) in blue (C′′, D′′, E′′, F′′). (G, H) Control-injected embryos contain *crestin*^+^ neural crest cells within the postotic vagal region and ventrally within two streams of migratory cells emanating toward the ventral midline along the foregut at 36 hpf (H; arrows). (I--L) Although Meis3 MO--injected and *pbcab*-injected embryos contain *crestin*^+^ neural crest ventrally within the postotic vagal regions, no streams of neural crest are detected migrating toward the ventral midline. (M) Bar graph quantifying the number of *sox10*:GFP^+^ neural crest cells near the gut in control and Meis3 MO-injected embryos at 36 hpf, \**p* \< 0.05. ba, branchial arch; e, eye; h, hyoid; ot, otic. Scale bars, 70 μm (A, B), 50 μm (C--F), 20 μm (E′′, F′′), 100 μm (G, I, K).](3728fig2){#F2}

To examine whether enteric neural crest localization was altered after loss of Meis3, we analyzed serial transverse sections from the postotic and foregut levels at 36 hpf. In control embryos, at the postotic level, *sox10:*GFP^+^ neural crest cells localized laterally ([Figure 2, C′ and C′](#F2){ref-type="fig"}′; *n* = 10/10), whereas posterior sections at the level of the foregut showed *sox10:*GFP^+^ enteric neural crest localized around the gut (arrows in [Figure 2, E′ and E′](#F2){ref-type="fig"}′; *n* = 10/10). Although postotic vagal neural crest cells were present in lateral regions after loss of Meis3 ([Figure 2, D′ and D′](#F2){ref-type="fig"}′), they were virtually absent along the foregut ([Figure 2, F′ and F′](#F2){ref-type="fig"}′; *n* = 8/10). Control embryos exhibited an average of 4 *sox10:*GFP^+^ cells along the foregut, whereas Meis3 morphants contained only an average of 0.33 *sox10:*GFP^+^ cells ([Figure 2M](#F2){ref-type="fig"}; *p* = 0.0053). To assess qualitatively neural crest cell distribution along the gut in whole mount, we performed *crestin* in situ hybridization ([Figure 2, G--L](#F2){ref-type="fig"}). In control embryos at 36 hpf, a ventral view revealed two chains of *crestin*-positive cells migrating from the left and right vagal regions to the ventral midline ([Figure 2H](#F2){ref-type="fig"}, arrows; *n* = 20/20). In Meis3 MO and *pbcab*-injected embryos, although *crestin*-positive cells resided within the vagal regions, no migratory chains toward the midline were detected ([Figure 2, J and L](#F2){ref-type="fig"}; *n* = 18/20 and 20/20, respectively). Taken together, these results suggest that Meis3 may be required for the timely migration of vagal neural crest cells into the developing ventral midline and foregut environment.

During the initial phases of ENS development, the endoderm is required for migration of vagal neural crest cells toward the ventral midline ([@B75]). One possibility is that the delay of vagal neural crest migration to the ventral midline in Meis3 morphants actually might reflect an absence of foregut endoderm. To examine this possibility, we assayed the presence of gut endoderm by in situ hybridization at 36 hpf using the digestive endoderm marker *foxa1* ([@B67]). Similar to control-injected embryos, Meis3 morphants possessed *foxa1*-positive gut endoderm territory (Supplemental Figure S2, A--D), as observed in both whole-mount (Supplemental Figure S2, A and B, *n* = 20/20) and sectioned embryos (Supplemental Figure S2, C and D, *n* = 6/6), suggesting that Meis3 is not required for the presence of gut endoderm. To assess whether Meis3 loss alters the specification of pancreatic endodermal progenitors, we also examined the expression of *pdx1* in control and Meis3 morpholino (MO)--injected embryos. During zebrafish pancreas specification, *pdx1*-positive endoderm gives rise to the dorsal pancreatic bud and the ventral pancreatic anlage by 32 hpf ([@B10]; [@B77]; [@B31]). No significant difference in the expression domain of *pdx1* was observed between control and Meis3 MO--injected embryos at 36 hpf (Supplemental Figure S2, E and F; arrows; *n* = 20/20). Thus Meis3 is likely not required for the specification or survival of gut and pancreatic endoderm, suggesting that vagal neural crest migration defects in Meis3-depleted embryos likely do not stem from a lack of foregut endoderm tissue.

Mesoderm-derived *hand2* is required for the efficient migration of enteric precursors along the gut in zebrafish embryos during ENS development ([@B75]). To investigate whether *hand2* localization was altered after loss of Meis3, possibly contributing to defects in enteric neural crest migration, we also examined *hand2* localization at 52 hpf by whole-mount in situ hybridization. Compared with control-injected embryos (Supplemental Figure S2G; arrows; *n* = 20/20), Meis3 morphants and *pbcab*-injected embryos exhibited largely normal *hand2* expression domains along the gut (Supplemental Figure S2, H and I; arrows; *n* = 18/20 and 17/20, respectively). These results suggest that Meis3 is not required for specification of *hand2*-positive mesoderm.

Meis3 is required for the efficient migration of enteric neural crest along the developing gut
----------------------------------------------------------------------------------------------

During early zebrafish ENS development, enteric neural crest cells migrate as two chains from the postotic vagal regions and subsequently along the left and right sides of the developing gut tube ([@B80]; [@B68]). Making their way caudally along it, they colonize more than one-fourth of the length of the gut by 54 hpf, and by 66 hpf, they reach the caudal end of the hindgut ([@B68]). These migratory enteric progenitor cells are marked by the expression of *phox2bb*, a transcription factor required for the specification of enteric neural crest fate ([@B29]). To investigate whether Meis3 is required for the specification of enteric neural crest fate and/or localization of enteric progenitors along the rostral-caudal axis of the gut, we performed in situ hybridization against *phox2bb*. In control embryos, the *phox2bb*^+^ cell population had left the postotic vagal region by 52 hpf ([Figure 3A](#F3){ref-type="fig"}, arrow) and migrated caudally, progressing along 40% of the length of the gut ([Figure 3D](#F3){ref-type="fig"}), as evidenced by two migratory streams of *phox2bb*^+^ enteric precursors localized along the left and right sides of the gut tube at midgut level ([Figure 3G](#F3){ref-type="fig"}; arrows, dorsolateral view; *n* = 30/30). In contrast, Meis3 morphants and *pbcab*-injected embryos possessed an expanded postotic vagal *phox2bb*^+^ domain at 52 hpf ([Figure 3, B and C](#F3){ref-type="fig"}; arrows; *n* = 25/30 and 28/30, respectively). Along the gut of Meis3 morphants, *phox2bb*^+^ enteric precursors were located more rostrally (at foregut level) than control embryos and had only progressed 25% of the length of the gut ([Figure 3, E and H](#F3){ref-type="fig"}; arrows, dorsolateral view). *pbcab*-injected embryos exhibited a more severe phenotype, with *phox2bb*^+^ enteric precursors located in the anterior foregut ([Figure 3, F and I](#F3){ref-type="fig"}; arrow, dorsolateral view), only migrating 10% of the length of the gut. In transverse sections, although control embryos had enteric precursors localized on the left and right sides of the gut tube along the posterior foregut ([Figure 3J](#F3){ref-type="fig"}, arrows), Meis3 morphants and *pbcab*-injected embryos had no detectable enteric precursors in a comparable location ([Figure 3, K and L](#F3){ref-type="fig"}). These results indicate that Meis3 is required for the timely and efficient migration of enteric neural crest to and along the developing gut but that their specification occurs normally.

![Localization of *phox2bb*^+^ neural crest along the gut is altered after loss of Meis3. Lateral views of *phox2bb* localization within the cranial regions of (A) control, (B) Meis3 morphant, and (C) *pbcab*-injected embryos at 52 hpf reveals that *phox2bb*^+^ vagal neural crest cells have left the vagal region of control embryos (arrow) but persist in Meis3 morphants and *pbcab*-injected dominant-negative embryos (arrows) at the same location. *phox2bb*^+^ enteric neural crest cells are localized along the left and right sides of the midgut in (D, G) control embryos, whereas enteric crest cells localize rostrally within the foregut of (E, H) Meis3 morphants and are present in the most anterior region of the foregut in (F, I) *pbcab*-injected embryos. Sectioned views confirm that although *phox2bb*^+^ enteric crest cells localize around the gut tube in (J) control embryos (arrows), they are not detected at the comparable level in (K) Meis3 morphant and (L) *pbcab*-injected embryos. Scale bars, 50 μm (A--F), 40 μm (G--I).](3728fig3){#F3}

To test further the hypothesis that loss of Meis3 function effects cell migration, we next used in vivo time-lapse confocal microscopy to examine directly enteric neural crest migration in control embryos compared with Meis3 morphants. To this end, we imaged the gut region of control and Meis3-morphant double-transgenic embryos positive for *sox10*:mRFP (membrane red fluorescent protein \[RFP\]^+^ neural crest) and *sox17*:GFP (GFP^+^ gut endoderm). Images were assumed laterally, as depicted in the schematic ([Figure 4A](#F4){ref-type="fig"}), during the second day in development (∼54--57 hpf), when enteric neural crest cells are migrating along the developing gut tube. In control embryos, *sox10*:mRFP^+^ neural crest cells were observed migrating caudally as a chain along the *sox17*:GFP^+^ midgut at a rate of 20 μm/h ([Figure 4C](#F4){ref-type="fig"}; arrows over time; *n* = 3; Supplemental Movie S1). In contrast, in Meis3 morphants, *sox10*:mRFP^+^ neural crest cells were observed at much more rostral locations along the *sox17*:GFP^+^ foregut at comparable times ([Figure 4A](#F4){ref-type="fig"}) and exhibited a much slower migration rate of 10 μm/h ([Figure 4B](#F4){ref-type="fig"}; arrows over time; *n* = 3; Supplemental Movie S2). Indeed, in agreement with *phox2bb* in situ analysis ([Figure 3](#F3){ref-type="fig"}), these observations indicate that enteric neural crest migration is compromised after loss of Meis3 and suggest that Meis3 is required for the efficient migration of enteric neural crest along the developing gut.

![Meis3 is required for efficient migration of enteric neural crest cells along the gut. (A) Schematic depicting where along the gut axis live time-lapse movies were acquired. Colored boxes depict where neural crest streams were observed in Meis3 morphant (red box) and Control embryos (green box). Lateral cropped view of time-lapse stills depicting *sox10*:mRFP^+^; *sox17*:GFP^+^ (B) Meis3 morphant and (C) control embryos over time during the second day in development (∼54--57 hpf). (B) In Meis3 morphant embryos, *sox10*:mRFP^+^ enteric neural crest chains were observed migrating at a rate of 10 μm/h along the posterior end of the foregut, where they migrated 30 μm within 3 h (arrow over time). In Meis3 morphants, the leading edge of the migratory front exhibited membrane protrusions caudally along the gut (small arrow). (C) In control embryos, *sox10*:mRFP^+^ enteric neural crest migratory chains were observed migrating at a rate of 23 μm/h along the midgut, where they migrated 70 μm within 3 h (arrow over time). Asterisks mark beginning of migratory front; bottom, merging shows location of *sox10*:mRFP^+^ enteric neural crest cells (red) along the *sox17*:GFP^+^ gut endoderm (green). Scale bar, 40 μm.](3728fig4){#F4}

Loss of Meis3 results in colonic aganglionosis during ENS development
---------------------------------------------------------------------

Because Meis3 loss results in perturbed enteric neural crest migration along the gut, it is possible that this may lead to defects in neuronal differentiation. During zebrafish enteric neuron differentiation, the first differentiating enteric neurons are detected along the anterior gut at ∼55 hpf ([@B29]; [@B68]), and by 74 hpf, Hu^+^ enteric neurons appear at the most caudal end of the gut, near the anus ([@B68]; [@B69]). To examine neuronal differentiation, we analyzed control, Meis3 MO, and *pbcab*-injected embryos by whole- mount immunohistochemistry at 96 hpf, when enteric neurons encompass the entire length of the gut, using antibodies against the panneuronal marker Hu ([Figure 5](#F5){ref-type="fig"}). In control embryos, Hu^+^ neurons were observed along the entire length of the gut, all the way to the anus ([Figure 5, A and D](#F5){ref-type="fig"}; *n* = 12). In Meis3 morphants, Hu^+^ neurons were only present within the foregut and midgut regions, with no Hu^+^ neurons detected in the hindgut ([Figure 5, B and E](#F5){ref-type="fig"}; *n* = 10/12), indicating the Meis3 loss results in colonic (hindgut) aganglionosis, a disorder in which the hindgut is devoid of neurons ([@B7]). Demonstrating a more severe phenotype, *pbcab*-injected embryos exhibited total intestinal aganglionosis, in which all but the foregut is devoid of neurons ([Figure 5, C and F](#F5){ref-type="fig"}; *n* = 12/12). Compared with control embryos, which contained an average of 95.6 Hu^+^ neurons along the entire gut ([Figure 5I](#F5){ref-type="fig"}, *n* = 8), Meis3-deficient embryos contained significantly less, with an average of 55.6 Hu^+^ neurons along the entire gut ([Figure 5I](#F5){ref-type="fig"}, *p* = 0.0004, *n* = 8), whereas *pbcab*-injected embryos contained only eight ([Figure 5I](#F5){ref-type="fig"}, *p* = 0.0001, *n* = 8).

![Loss of Meis3 leads to colonic aganglionosis during ENS development. Whole-mount immunohistochemistry against Hu at 96 hpf reveals enteric neurons present throughout the entire length of the gut of (A) control embryos, while they are absent from the hindgut region of (B) Meis3 morphants and present only within the foregut of (C) *pbcab*-injected embryos. (D) Zoomed-in view from A shows enteric neuron density and morphology in control embryos, whereas zoomed-in views from (E) Meis3 morphants in B and (F) *pbcab*-injected embryos in C reveal fewer neurons present after loss of Meis3. (G, J) Whole-mount immunohistochemistry against 5HT neurotransmitter in control embryos reveals the presence of terminally differentiated neurons throughout the gut. (H, K) In Meis3 morphants, the presence of 5HT^+^ terminally differentiated neurons was evident within the foregut and midgut but not the hindgut region, marked by asterisk. (I) Graph quantifying total Hu neurons in control-, Meis3 MO--, and *pbcab*-injected guts at 96 hpf, as well as total 5HT neurons within the foregut-midgut of control and Meis3 morphant guts. \*\**p* \< 0.05; \*\*\**p* \< 0.01. Error bars indicate ± SEM. Scale bar, 80 μm (A-- C, G, H), 30 μm (D--F, J, K).](3728fig5){#F5}

We also examined the localization of 5-hydroxytryptamine (5HT) neurotransmitter as an indicator of terminal differentiation. In control embryos, 5HT was detected in the gut ([Figure 5, G and J](#F5){ref-type="fig"}), with control foregut--midgut regions containing an average of 19.5 5HT^+^ neurons ([Figure 5I](#F5){ref-type="fig"}; *n* = 8). In Meis3 morphants, 5HT^+^ neurons were detected, with an average of 13.25 5HT^+^ neurons in the foregut--midgut region ([Figure 5, H, I, and K;](#F5){ref-type="fig"} *p* = 0.018, *n* = 6); however, no neurons were detected in the hindgut ([Figure 5H](#F5){ref-type="fig"}, asterisk). Therefore, although Meis3-deficient enteric neural crest cells have the capacity to differentiate into enteric neurons, there are fewer of them compared with control and they are absent from the hindgut. Taken together, these data suggest that Meis3 is required for efficient colonization of the entire gut ([Figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}) such that its loss causes a deficit of enteric neurons within the hindgut region ([Figure 5](#F5){ref-type="fig"}).

Loss of Meis3 results in a decrease in the number and proliferation of enteric neural crest cells around the gut
----------------------------------------------------------------------------------------------------------------

The observation that decreased numbers of enteric neurons form within the ENS in Meis3-deficient embryos ([Figure 5I](#F5){ref-type="fig"}) suggests that Meis3 might play an important functional role in controlling the appropriate number of enteric neurons that are born during development. Enteric neural crest cells actively proliferate as they migrate ([@B72]; [@B68]). One current model for gut colonization is that neural crest cells undergo a proliferative expansion into new gut territory as they migrate, driving the neural crest front forward ([@B49]). Accordingly, the decreased efficiency of neural crest migration and diminished enteric neuron formation may reflect a decrease in precursor cell number and/or their proliferation during migration.

To test this possibility, we performed immunohistochemistry on serial transverse cryosections at caudal foregut levels at 52 hpf and quantified the number of neural crest cells near the gut ([Figure 6](#F6){ref-type="fig"}). In control sections, *sox10*:GFP^+^ enteric neural crest cells were abundantly detected around the gut ([Figure 6, A--A′′, D, and D′](#F6){ref-type="fig"}, arrows), with an average of 15 cells/section ([Figure 5G](#F5){ref-type="fig"}, *n* = 6). In Meis3 morphants, the number of *sox10*:GFP^+^ neural crest cells was significantly reduced, with an average of 6.7 cells/section ([Figure 6, B--B′′, E, E′, and G](#F6){ref-type="fig"}; *p* = 0.0012, *n* = 6). Similarly, *pbcab*-injected embryos exhibited only 4.5 cells/section ([Figure 6, C--C′′, F, F′, and G](#F6){ref-type="fig"}; *p* = 0.0002, *n* = 6). To determine whether the cell number defect in Meis3 morphants could be rescued, we coinjected *meis3* mRNA, which cannot be bound by Meis3 MO, with Meis3 MO into *sox10*:GFP embryos and analyzed it at 48 hpf by immunohistochemistry. Control embryos exhibited an average of 12 *sox10*:GFP^+^ enteric neural crest cells near the gut ([Figure 6, H and K](#F6){ref-type="fig"}, *n* = 6), whereas Meis3 morphants contained significantly fewer, on average 5.3 ([Figure 6, I and K](#F6){ref-type="fig"}; *p* = 0.0075, *n* = 6). Coinjection of embryos with Meis3 MO and *meis3* resulted in a partial rescue in neural crest cell number around the gut, with embryos exhibiting an average of 9.6 *sox10*:GFP^+^ cells, a significant increase compared with Meis3 morphants ([Figure 6, J and K](#F6){ref-type="fig"}; *p* = 0.01, *n* = 6).

![Meis3 function is required for the proper number of enteric neural crest cells around the gut and for their proliferation. By use of immunohistochemistry, enteric neural crest cell numbers were analyzed in (A--A′′) control-, (B--B′′) Meis3 MO--, and (C--C′′) *pbcab*-injected *sox10*:GFP^+^ embryos at 52 hpf. Zoomed-in views of control- (D, D′), Meis3 MO-- (E, E′), and *pbcab*-injected embryos (F, F′) reveal fewer enteric neural crest cells near the gut after loss of Meis3 or Meis function; *sox10*:GFP (green), F-actin (red), and DAPI (blue). (G) Bar graph showing quantification of enteric neural crest near the gut in control-, Meis3 MO--, and *pbcab*-injected embryos at 52 hpf. (H--K) Rescue experiment immunohistochemistry and quantification showing that coinjection of *meis3* mRNA, which cannot be bound by Meis3 MO, along with Meis3 MO (J) was sufficient to partially rescue enteric neural crest cell number near the gut at 48 hpf (K) when compared with injection of Meis3 MO alone (I, K); *sox10*:GFP (green), F-actin (red). (L) Control immunohistochemistry against the mitotic marker pH3 at 52 hpf and in (M) Meis3 MO--injected embryos; *sox10*:GFP (green), pH3 (red), and DAPI (blue). (N) Bar graph showing quantification of mitotic neural crest around the gut in control- and Meis3 MO--injected embryos. For all graphs, \**p* \< 0.05; \*\**p* \< 0.01. Error bars indicate ± SEM. Scale bars, 40 μm (A--C), 20 μm (D--F), 20 μm (H--M).](3728fig6){#F6}

To test the hypothesis that reduced neural crest cell number in Meis3 morphants could be due to changes in their proliferation, we analyzed cell division in serial transverse sections using an antibody against phospho--histone H3, which marks mitotic cells in G2/M phase of the cell cycle. In control sections, mitotic *sox10*:GFP^+^ cells were present around the gut at an average of two cells/section ([Figure 6, L and N](#F6){ref-type="fig"}, arrow; *n* = 6), whereas Meis3 MO--injected embryos exhibited fewer than an average of one mitotic cell ([Figure 6, M and N](#F6){ref-type="fig"}, arrow; *p* = 0.02, *n* = 6). Collectively these quantitative data suggest that Meis3 is necessary for the correct numbers of enteric neural crest cells around the gut and for their proliferation, suggesting that the paucity of enteric neurons later in development results, at least partially, from reduction of the total migratory population.

Sonic Hedgehog pathway is disrupted after loss of Meis3
-------------------------------------------------------

Shh signaling is required for proper ENS patterning and development in mice and zebrafish ([@B83]; [@B96]; [@B75]; [@B86]) and for the proliferation and differentiation of enteric neural crest cells in explant culture ([@B34]) and zebrafish embryos ([@B75]). Moreover, previous experiments showed that the dominant-negative Pbx4 construct *pbcab* leads to reduced endodermal *shh* expression domain ([@B25]).

To determine whether Meis3 loss altered Shh pathway component expression during ENS phases of development, we performed in situ hybridization against *shha*, the zebrafish Shh orthologue, and *ptch2* (zebrafish orthologue of Ptc1, formerly known as *ptc-1*) at 36 and 52 hpf in control and Meis3 MO--injected embryos. In control embryos at 36 hpf, *shha* transcript was observed in the notochord, fin buds, and endoderm ([Figure 7, A and B](#F7){ref-type="fig"}; arrows, *n* = 30/30). In Meis3 MO--injected embryos, *shha* was detected in the notochord but not in the fin buds or the endoderm ([Figure 7, C and D](#F7){ref-type="fig"}; arrow, *n* = 28/30). Accordingly, expression of the Shh receptor *ptch2* was also reduced in the fin buds and diminished within the anterior foregut region in Meis3 MO--injected embryos ([Figure 7, G and H](#F7){ref-type="fig"}; dashed lines; *n* = 26/30) compared with control ([Figure 7, E and F](#F7){ref-type="fig"}; *n* = 30/30 normal). At 52 hpf, the lack of fin bud and endodermal *shha* expression was still pronounced in Meis3 MO--injected embryos ([Figure 7, K and L](#F7){ref-type="fig"}; arrow, *n* = 28/30) compared with control embryos ([Figure 7, I and J](#F7){ref-type="fig"}; *n* = 30/30 normal). By contrast, the foregut expression domain of *ptch2* appeared expanded in Meis3 MO--injected embryos ([Figure 7, O and P](#F7){ref-type="fig"}; dashed lines; *n* = 27/30) compared with controls ([Figure 7, M and N](#F7){ref-type="fig"}; *n* = 30/30 normal). To obtain enhanced resolution of the *shha* and *ptch2* expression territories around the gut, we imaged sections after in situ hybridization at 52 hpf. In control sections, expression of *shha* was detected in the gut endoderm ([Figure 7Q](#F7){ref-type="fig"}, arrow), and *ptch2* was observed in the surrounding mesenchyme ([Figure 7S](#F7){ref-type="fig"}). By contrast, in Meis3 MO--injected embryos, *shha* was reduced ([Figure 7R](#F7){ref-type="fig"}), whereas *ptch2* was increased ([Figure 7T](#F7){ref-type="fig"}, arrows).

![Meis3 loss is sufficient to alter the expression of Sonic Hedgehog pathway components during ENS phases of development. The expression of *shha* and *ptch2* was examined by in situ hybridization at 36 hpf in control- (A, B and E, F, respectively) and Meis3 MO--injected embryos (C, D and G, H, respectively) and at 52 hpf in control- (I, J and M, N, respectively) and Meis3 MO--injected embryos (K, L and O, P, respectively). Dorsal views in A, E, C, and G at 36 hpf and I, M, K, and O at 52 hpf. Lateral views in B, F, D, and H at 36 hpf and J, N, L, and P at 52 hpf. At 52 hpf, transverse sections through the gut revealed *shha* expression in gut endoderm of control embryos (Q, arrow) and its absence in Meis3 MO--injected embryos (R), whereas *ptch2* was expanded in Meis3 MO--injected embryos (T, arrows) compared with control embryos (S). The expression domain of *ptch2* along the gut (dashed lines) in control embryos treated with DMSO (U) and in Meis3 MO--injected embryos (V). Cyclopamine treatment from 32 to 52 hpf was sufficient to reduce *ptch2* gut expression (dashed lines) in control- (W) and Meis3 MO--injected embryos (X) compared with treatment of DMSO alone. Scale bars, 70 μm (A--P, U--X), 20 μm (Q--T).](3728fig7){#F7}

Although Ptch1 is a negative regulator of the Hedgehog pathway, it is also up-regulated in response to Smoothened-dependent Hedgehog signaling activity ([@B23]; [@B52]; [@B41]). To ascertain whether the expansion in *ptch2* expression could be smoothened dependent, we treated control and Meis3 MO--injected embryos with 10 μM cyclopamine, a steroidal Hedgehog pathway inhibitor that acts by binding Smoothened ([@B18]), or dimethyl sulfoxide (DMSO) from 32 to 52 hpf and assayed the expression of *ptch2* by in situ hybridization. In control embryos treated with DMSO, *ptch2* was expressed broadly in the anterior foregut region and narrowed around the gut tube caudally ([Figure 7U](#F7){ref-type="fig"}; dashed lines; *n* = 20/20). Meis3 MO--injected embryos treated with DMSO had laterally expanded *ptch2* expression domains along the length of the gut ([Figure 7V](#F7){ref-type="fig"}; dashed lines; *n* = 17/20). Meis3 MO--injected embryos treated with cyclopamine were largely "rescued" and exhibited reduced *ptch2* expression fields ([Figure 7X](#F7){ref-type="fig"}; *n* = 20/20), similar to control embryos ([Figure 7W](#F7){ref-type="fig"}; *n* = 20/20). This notable rescue suggests that *ptch2* up-regulation in Meis3-deficient embryos is due to elevated Hedgehog signaling.

DISCUSSION
==========

Meis transcription factors are members of the TALE homeodomain subclass of protein involved in the intrinsic control of varied roles during embryonic development (for review, see [@B61]; [@B16]). They are best known to function as part of a dimeric or trimeric complex, along with Pbx and/or Hox transcription factors, in order to regulate activation of target genes in a tissue-specific manner. For example, in zebrafish and mouse embryos, Meis1/2 and Hoxb1b bind the promoter of *Hoxb1a* to influence the magnitude of transcriptional output in a conserved and temporal manner during branchial arch development ([@B19]). In this study, we identified zebrafish Meis3 as a novel factor involved in ENS development. Meis3 loss was sufficient to perturb enteric neural crest proliferation and migration along the developing gut in zebrafish embryos. As a result, fewer enteric neurons were born in the ENS, leading to colonic aganglionosis---directly implicating Meis3 in ENS development and highlighting it as a novel candidate gene in Hirschsprung's disease. Indeed, Meis3 loss resulted in the aberrant expression of Shh pathway components, which have known roles in the etiology of this disorder.

During ENS development, enteric neural crest precursors must proliferate in order to create sufficient numbers of enteric neurons and glial cells needed to populate the mature ENS. In humans, for instance, the total number of neurons rivals those found in the spinal cord, with numbers between 200 million and 600 million ([@B35]). Therefore enteric neural crest cells must maintain proliferation and prevent differentiation until the appropriate time, all while migrating through the gut. Our results demonstrate that Meis3 loss of function decreases the number of enteric precursors and their proliferation during zebrafish ENS development, contributing to ENS defects during later phases of development. This suggests that Meis3, in conjunction with yet-unknown cofactors, participates in controlling enteric precursor proliferation in order to ensure that the appropriate number of neurons is generated throughout the gut. Meis proteins have well-described roles in proliferation control in various tissues, making them logical candidates for proliferative regulators in neural crest cells. For example, Meis1 protein regulates the proliferative expansion of retinal progenitors during early phases of retinogenesis in zebrafish embryos by directly modulating the expression of *ccnd1* (CyclinD1), a cell cycle progression factor ([@B9]). Meis1 expression is associated with high levels of proliferation in neuroblastoma ([@B36]), and its forced expression in immortalized myeloid progenitors leads to maintenance of self-renewal and blocks differentiation ([@B13]). Meis2 is known as a player in the pathogenesis of cancer; its presence is essential for neuroblastoma proliferation via direct influence on progression of the M phase ([@B94]). In the frog hindbrain, using ectopic expression and knockdown of Meis3, [@B28]) showed that Meis3 is necessary and sufficient to induce the proliferation of neural progenitors while inhibiting their precocious differentiation downstream of Wnt signaling.

In addition to implicating Meis3 in regulation of enteric neural crest cell number, our experiments reveal a potential role for Meis proteins in migration of the neural crest. Although it has no effect on enteric neural crest specification, Meis3 loss causes a delay in the migration of vagal neural crest to the foregut and decreases the efficiency of migration of enteric neural crest along the gut. Meis3-deficient enteric neural crest migrated much more slowly along the gut than did control enteric crest, as assayed by monitoring the localization of enteric progenitors using the marker *phox2bb* ([Figure 3](#F3){ref-type="fig"}) and live imaging of *sox10*:mRFP+ neural crest migration along the gut ([Figure 4](#F4){ref-type="fig"}). The combined effects of decreased proliferation and slower migration contribute to diminished colonization of the caudal regions of the gut. We hypothesize that this leads to colonic aganglionosis. It is possible that defects in proliferation may attenuate the migratory progress of enteric crest to and along the gut as well, significantly contributing to lack of gut colonization. Indeed, enteric neural crest cells are highly proliferative during migration, and this proliferation is believed to drive the migratory front forward during gut colonization ([@B49]). Although Meis1 has been implicated in influencing early induction of neural crest cell fate in frog embryos ([@B55]), there were no previously published reports of the Meis family playing a role in regulation of neural crest migration. Of interest, however, Meis protein expression has been described in diverse migratory cell types. For example, Meis1 is expressed in migratory cortical neurons of the embryonic mouse brain and neuroblastoma cancer cells ([@B32]), and Meis 1/2/3 protein was detected within migratory and proliferative cerebellar neural stem cells of the adult brown ghost knifefish brain, implying functional roles for the Meis genes in proliferation and migration during adult homeostasis and regeneration ([@B81]). Here we describe *meis3* expression within a subset of vagal neural crest cells migrating into the foregut ([Figure 1](#F1){ref-type="fig"}). Of importance, all of these studies in varied model organisms suggest that Meis regulation may be a conserved method that cells use during tissue development, cell homeostasis, and cancer metastasis to regulate proliferation and migration.

Other transcription factors in addition to Meis3 have been shown to play roles in ENS development. Intrinsically, the transcription factor *Phox2b* is required for enteric cell fate specification in amniotes and zebrafish ([@B71]; [@B29]), and is required for *Ret* expression in the ENS ([@B71]). Highlighting its conserved and integral role in ENS development, zebrafish and mouse mutants for the transcription factor *Sox10* completely lack ENS ([@B73]; [@B44]; [@B27]; [@B15]), and *Sox10* is required for the expression of *Phox2b* ([@B45]; [@B29]), indicating that it lies upstream of enteric neural crest specification. In addition, mutation or loss of *Foxd3* ([@B62]; [@B82]), *Tfap2α* ([@B4]), *Pax3* ([@B60]), *Hoxb5* ([@B53]; [@B43]), and *Hand2* ([@B75]) all result in either a lack of enteric neural crest colonization of the gut or perturbed ENS development, highlighting the complexity of ENS development. Possible candidates for binding partners of Meis3 include *pbx1a*, which is expressed in the zebrafish vagal and foregut environment ([@B85]), and *hoxb3a* and *hoxb5b*, which are expressed in the postotic vagal regions and gut mesoderm during enteric neural crest phases of development ([@B47]; [@B40]). In the mouse, both Hoxb3 and Hoxb5 have been implicated in vagal and enteric neural crest migration and development ([@B17]; [@B53]). In addition, we cannot rule out the possibility that other Meis proteins in addition to Meis3 are important for ENS development.

The Shh signaling pathway plays conserved roles in regulating the patterning, proliferation, and differentiation of various cell types (for review, see [@B22]). During ENS development in chicken embryos, temporally inhibiting Sonic hedgehog pathway activity with cylopamine leads to increased enteric neuron number, along with enhanced smooth muscle differentiation ([@B83]). In mice, loss of *Shh* ectopically expands neuron distribution throughout the gut ([@B96]). In contrast, loss of *shha*, *smoothened*, or cilia function in zebrafish leads to complete loss of enteric neural crest cells in the gut at all phases of ENS development ([@B75]; [@B86]; [@B87]), whereas overexpression of *shha* creates an overabundance of enteric neural crest cells along the gut ([@B75]). Thus the role of Shh in ENS development varies considerably among species.

Testing the hypothesis that the Shh signaling pathway was disrupted after Meis3 loss, we discovered that the expression of *shha* and its receptor *ptch2* was decreased during early phases of enteric neural crest migration, at 36 hpf. During later phases of ENS development, at 52 hpf, however, we observed that although *shha* was diminished in the gut environment, the expression of *ptch2* was expanded in a Smoothened-dependent manner, as incubation of Meis3 morphants in cyclopamine was sufficient to rescue the expansion of *ptch2* at 52 hpf. These results suggest that the Hedgehog signaling pathway is disrupted after loss of Meis3. In mice, it was previously shown that Indian Hedgehog (Ihh) is expressed in the developing gut epithelium and its loss results in ENS defects, similar to what is seen in Hirschsprung's disease ([@B96]; [@B58]). *ihha* is expressed during zebrafish intestinal development and required for the proper development of the gut and ENS ([@B93]; [@B46]). One possibility is that *ihha* is up-regulated in Meis3 morphants, contributing to ENS defects during development. Alternatively, Meis3 may directly effect the expression of *ptch2* to influence ENS development. Indeed, Ptch1 has recently been implicated as a novel factor involved in the pathogenesis of Hirschsprung's disease; in humans and mice, single- nucleotide polymorphisms have been associated with high risk for this disorder, and conditional loss of Ptch1 within enteric neural crest cells causes a decreased ability to differentiate into enteric neurons in culture ([@B64]). Collectively the results suggest a model in which loss of Meis3 effects Shh activity during early phases of vagal neural crest entry into the gut, leading to a delay in gut invasion, while also contributing to perturbed migration along the gut during later phases.

MATERIALS AND METHODS
=====================

Zebrafish maintenance
---------------------

Zebrafish (*Danio rerio*) were maintained at 28.5°C on a 13-h light/11-h dark cycle. Animals were treated in accordance with California Institute of Technology Institutional Animal Care and Use Committee provisions.

Morpholino, mRNA injections, and mRNA rescue experiment
-------------------------------------------------------

Meis3 MO (5′-ATCCATGCGATACGGAAGCCGAGCT-3′; Genetools, LLC, Philomath, OR; [@B25]) directed against the 5′ untranslated region of *meis3* was used in morpholino knockdown experiments. Standard control MO (5′-CCTCTTACCTCAGTTACAATTTATA-3′) was used as a negative control. Wild-type AB strain and Tg(-4.9*sox10*:GFP) ([@B15]) were injected with 2.3 nl of 0.75 mM Meis3 MO at the one-cell stage using a Nanoliter 2000 injector (World Precision Instruments, Sarasota FL). For *pbcab* injections, the pCS2-*pbcab-myc* construct ([@B21]), which encodes a truncated version of the *pbx4* gene tagged with myc, was linearized with *Not*1, and capped mRNA was transcribed using the Sp6 RNA synthesis kit (Ambion, Waltham, MA). A 200-pg amount of *pbcab* was injected into one-cell-stage embryos for dominant-negative experiments. For mRNA rescue experiments, the *meis3* coding sequence was PCR amplified from a 28-hpf zebrafish cDNA library starting from the start codon, thereby removing 19 base pairs of morpholino recognition sequence, with primers to add a 5′ *Eco*RI restriction site and a 3′ *Xba*I restriction site, respectively, as follows: forward, 5′-CGGAATTCCATGGATAAGAGG-3′; and reverse, 5′-GCTCTAGATCAGTGGGCATGT-3′. The resulting *meis3* PCR fragment was then gel excised, digested with *Eco*RI and *Xba*I, directionally cloned into pCS2+, and sequence verified. pCS2-*meis3* was linearized with *Not*I and used as a template to generate *meis3* capped mRNA with the Sp6 RNA synthesis kit (Ambion). A 150-pg amount of *meis3* mRNA was coinjected with Meis3 MO for rescue experiments at the one-cell stage and embryos fixed at 48 hpf for immunohistochemistry as described later or processed at 25 hpf for Western blot analysis.

Western blot
------------

Control-injected and Meis3 MO--injected embryos were anesthetized using tricaine, deyolked manually using fine forceps, and transferred to 1.7-ml Eppendorf tubes on ice. Embryos were rinsed twice in 1× phosphate-buffered saline (PBS) and then immediately homogenized in protein lysis buffer (5 mM EDTA, 50 mM Tris, pH 8, 100 mM NaCl, 1% NP-40) supplemented with Complete protease inhibitor (Roche, Madison, WI). Protein homogenate was denatured using Invitrogen NuPAGE LDS sample buffer and reducing agent per manufacturer's instructions, loaded, and run in a Novex Bis-Tris SDS--PAGE gel. Proteins were transferred onto nitrocellulose membrane, blocked in 5% milk/1× PBS/Tween-20 (PBST) for 1 h at room temperature and incubated in rabbit anti-Meis3 (1:1000; ab82761; Abcam, Cambridge, MA) overnight at 4°C. The blot was incubated in horseradish peroxidase--conjugated anti-rabbit secondary 1:13,000 for 2 h at room temperature and developed using the GE Healthcare ECL detection system.

Riboprobes and in situ hybridization
------------------------------------

Hybridizations were performed essentially as described ([@B42]). All experiments were repeated using three biological replicates. The following cDNA constructs were used as templates to generate riboprobes for whole-mount in situ hybridization: *meis3* ([@B74]), *crestin* ([@B54]), *foxa1* ([@B67]), *pdx1* ([@B10]), and *ptch2* ([@B51]). The following cDNAs were PCR amplified from a 28-hpf cDNA library, ligated into pGEM-Teasy vector, linearized, and used as templates to generate probe: *phox2bb*, forward, 5′-TTCCTTCTCCACTGACCCTT-3′, and reverse, 5′-CGTCGCTTCTTTTCTCCATC-3′; *hand2*, forward, 5′-TGGTTCGCCGTAGGGTATAG-3′, and reverse, 5′-TCTTGTCATTGCTGCTCCCT-3′; *shha*, forward, 5′-CTACGGCAGA­AGAAGACAT-3′, and reverse, 5′-CTGGCCGCTATCATCAACAA-3′.

Immunohistochemistry
--------------------

For immunohistochemistry processing, embryos were fixed overnight at 4°C in 4% paraformaldehyde (PFA), washed three times in 1× PBS, and incubated in 15% sucrose/1× PBS overnight at 4°C. Embryos were then incubated at 38°C in 7.5% gelatin/15% sucrose overnight, aligned in rubber molds, and snap frozen in liquid nitrogen. Cryoblocks were sectioned at 12 μm and mounted onto glass slides, and gelatin was removed by incubating slides in 1× PBS in a slide holder at 42°C for 20 min. Immunohistochemistry was then performed as previously described ([@B88]). The following antibodies were used on sections: rabbit anti-GFP 1:500 (A-11122; Life Technologies, Waltham, MA), goat anti-GFP 1:250 (ab6673; Abcam), and rabbit anti-pH3 1:250 (EMD Millipore, Billerica, MA). The following secondary antibodies were used: Invitrogen Alexa Fluor goat anti-rabbit 488, donkey anti-goat 488, and goat anti-rabbit 568 were used at 1:700. Hoechst 3358 and/or Alexa Fluor 568 phalloidin were included in with secondary incubations. For whole-mount immunohistochemistry, embryos at 28, 36, or 96 hpf were fixed overnight at 4°C in 4% PFA, rinsed three times in 1× PBS, incubated in 100% methanol at −20°C for 1 h, and then rehydrated stepwise into 1× PBS at room temperature. Embryos were then incubated in 100% acetone at −20°C for 11 min, rinsed three times in 1× PBS, and then digested at room temperature in 10 μg/ml Proteinase K for 12 min (28 hpf), 16 min (36 hpf), or 45 min (96 hpf). Embryos were then rinsed three times in 1× PBS, fixed for 10 min in 4% PFA at room temperature, rinsed three times in 1× PBS, and then incubated in 5% normal goat serum block diluted in 1× PBST supplemented with 1% dimethyl sulfoxide (DMSO) for 3 h. Embryos were then incubated in rabbit anti-GFP 1:500 (A-11122; Life Technologies), mouse anti-HuC/D 1:200 (Invitrogen, Waltham, MA), or rabbit anti-5HT 1:1000 (Immunostar, Hudson, WI) overnight at 4°C. Embryos were then washed out of primary antibody in 1× PBST and then incubated at room temperature in the secondary antibody Alexa Fluor goat anti-rabbit 488 or goat anti-mouse 568 (1:700; Invitrogen) for 3 h at room temperature. Embryos were rinsed in 1× PBST and imaged in 75% glycerol/1× PBS on a Zeiss 710 two-photon confocal microscope at the Beckman Imaging Center, California Institute of Technology.

Time-lapse imaging
------------------

Embryos positive for Tg(*sox10*:mRFP) and Tg(*sox17*:GFP) were mounted laterally in 1% low-melt agarose dissolved in fish water supplemented with 1× *N*-phenylthiourea and tricaine anesthetic in an imaging chamber. *Z*-stacks of 10--13 μm were acquired every 5 min for ∼3 h using a 20× objective on a Zeiss LSM 710 microscope. *Z*-stacks were compiled and exported using Imaris Image Analysis software.

Quantification and statistics
-----------------------------

For all experiments, three biological replicates were used, with *n* ≥ 6 for each experiment. For cell counts on sections, counts were performed on adjacent sections for each embryo and averaged. All graphs and calculations of statistical significance and SEM were performed using a two-parameter unpaired *t* test (GraphPad Prism).

Inhibitor experiments
---------------------

A master stock of 10 mM cyclopamine (Sigma-Aldrich \[St. Louis, MO\]; C4116-1MG) was made in DMSO and stored at −80°C. Control- and Meis3 MO--injected embryos were incubated in 10 μM cyclopamine or DMSO in embryo medium between 32 and 52 hpf at 28.5°C and then immediately fixed and processed for in situ hybridization as described.
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